PAROXETINE, PROLONGED EXPOSURE, AND BIOLOGY IN PTSD

帕罗西汀、长期接触以及 PTSD 中的生物学

• 批准号: 2889888
• 负责人: RANDALL Dean MARSHALL
• 金额: $ 16.21万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2889888
• 关键词: behavior test; behavioral /social science research tag; clinical chemistry; clinical research; clinical trials; cognition; cognitive behavior therapy; combination therapy; cortisol; human ecology; human subject; human therapy evaluation; mental disorder chemotherapy; mental disorder diagnosis; outcomes research; paroxetine; pharmacokinetics; posttraumatic stress disorder; social psychology

Posttraumatic Stress Disorder (PTSD) is a debilitating, often chronic disorder with serious psychiatric morbidity among civilians. The incidence in the U.S. is estimated at 1 % to 3%, although rates can be considerable higher in vulnerable populations. In traumatized groups such as rape and severe assault victims, the rate of PTSD can approach 50%. Little is known regarding effective pharmacologic and psychosocial treatment in civilians with PTSD, as the majority of research to date has been conducted in war veterans. This grant proposes a five year training and research program, which encompasses 3 major research domains of PTSD: pharmacologic treatment, psychosocial treatment, and biological correlates of clinical symptoms. Training would be accomplished in intensive supervision with the mentor (Michael Liebowitz, M.D.) and scientific advisors; course work; tutorials in major research centers; collaboration with established investigators; and original research projects. Five interrelated projects are proposed: 1) a double-blind, placebo-controlled, 12-week trial of paroxetine in PTSD; 2) development of a time-limited individual psychotherapy which integrates cognitive-behavioral and psychodynamic principles; 3) a systematic open trial of the integrated psychotherapy; 4) measurement of cortisol levels pre- and post-treatment in both clinical treatments; 5) assuming positive findings in #1 and #3, development of a clinical trial to assess the efficacy of paroxetine, pill- placebo, psychotherapy, and combined paroxetine and psychotherapy. It is hypothesized that both paroxetine and psychotherapy will be effective for PTSD, and that the combination might be superior to either treatment alone.

创伤后应激障碍（PTSD）是一种使人衰弱的， 在平民中造成严重精神病的疾病。发生率 在美国，估计为1%至3%，尽管利率可能相当高 在弱势群体中更高。 在遭受创伤的群体中， 对于严重袭击受害者，创伤后应激障碍的发病率可接近50%。 关于有效的药理学和心理社会学知之甚少 治疗平民创伤后应激障碍，因为大多数研究迄今为止， 在退伍军人中进行。该补助金提供了为期五年的培训 和研究计划，其中包括创伤后应激障碍的3个主要研究领域： 药物治疗、心理社会治疗和生物学相关因素 临床症状。培训将在密集的 导师的监督（Michael Liebowitz，医学博士）和科学 顾问;课程工作;主要研究中心的教程;协作 与既定的调查人员;和原始的研究项目。五 提出了相互关联的项目：1）一个双盲，安慰剂对照， 12-帕罗西汀在PTSD中的一周试验; 2）开发一个有时限的 个体心理治疗，将认知行为和 心理动力学原则; 3）系统的开放试验的综合 心理治疗; 4）治疗前和治疗后皮质醇水平的测量 在两种临床治疗中; 5）假设在#1和#3中的阳性发现， 开展临床试验，以评估帕罗西汀，药丸， 安慰剂、心理疗法和帕罗西汀与心理疗法的组合。 是 假设帕罗西汀和心理治疗对 PTSD，并且联合治疗可能上级单独治疗。